Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 8Recruiting 3Active not recruiting 3Withdrawn 2Not yet recruiting 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 5mCRPC 1Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Exercise 8Standard of Care 5trametinib 3tislelizumab 3Radiotherapy 3Radiosurgery 3Palliative Care 3Paclitaxel 3Gemcitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2cemiplimab 2Therapeutics 2Surveys and Questionnaires 2Resistance Training 2Oxaliplatin 2Nivolumab 2Maintenance 2Immune Checkpoint Inhibitors 2Drug Therapy 2Cisplatin 2Carboplatin 2vedolizumab 1toripalimab 1surufatinib 1sparsentan 1sintilimab 1semaglutide 1posaconazole 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms × enzalutamide × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡